Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06761183 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Preliminary Efficacy of NXL-001 in Patients With Ischemic Stroke

Name: Safety and Preliminary Efficacy of NXL-001 in Patients With Ischemic Stroke — clinical trial record (NCT06761183)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: NXL-001

StatusRecruiting

PhaseEarly Phase 1

SponsorBeijing Tiantan Hospital

Started2025-01-31

View on ClinicalTrials.gov ↗

This is a single-arm, open-label, single center, dose-escalation exploratory clinical study to evaluate the safety and tolerability of a single intracerebral injection of NXL-001, a NeuroD1 base gene therapy, in patients with chronic neuronal deficits from ischemic stroke.

Amendment history 3 changes detected by DataLookout

2026-09-10

Recruitment opened

2026-09-10

Primary completion pushed: 2026-12-31 → 2027-12-31

2026-09-10

Completion pushed: 2026-12-31 → 2027-12-31

Trial Details

NCT Number	NCT06761183
Lead Sponsor	Beijing Tiantan Hospital
Conditions	Ischemic Stroke
Enrollment	9 participants
Start Date	2025-01-31
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-09-09